A new 'Godzilla' weight‑loss jab could help tackle arthritis, heart disease and sleep apnoea - while also driving dramatic slimming, a major trial suggests.
Researchers found retatrutide helped 45 per cent of patients lose at least 30 per cent of their body weight, with some achieving results close to those seen with bariatric surgery.
But scientists say the drug's impact goes far beyond weight loss.
As well as helping patients shed pounds, the treatment improved blood sugar control, reduced cardiovascular risk factors and cut knee osteoarthritis pain by around 70 per cent.
It also showed potential to ease sleep apnoea, underlining its ability to tackle multiple serious conditions linked to obesity.
